Trial Profile
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Ribociclib (Primary) ; Fulvestrant
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms MAINTAIN
- 07 Jun 2022 Primary endpoint (Percent progression-free at 24 weeks) has been met according to the results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 Results assessing the efficacy of fulvestrant or exemestane +/- ribociclib in pts with HR+HER2- MBC whose cancer previously progressed on any CDK 4/6i + any ET presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 17 Feb 2022 Status changed from recruiting to active, no longer recruiting.